Literature DB >> 9124830

New pharmacokinetic in vitro model for studies of antibiotic activity against intracellular microorganisms.

K Hultén1, R Rigo, I Gustafsson, L Engstrand.   

Abstract

The capacity for intracellular growth is an important survival strategy for a large group of common pathogens. Helicobacter pylori, the etiological agent for gastritis and duodenal ulcer, has been shown by both in vivo and in vitro studies to have the capacity to invade epithelial cells. In vitro models are used to study the effect of antibiotics on microoganisms. Most investigations are performed in broth culture or on agar plates, but kinetic models for bacteria in broth have been described. We present a new, kinetic model adapted for intracellular pathogens. A glass chamber, with a metal rack fitting Falcon cell culture inserts, was connected to a pump by rubber tubes. Different tube diameters and pump speeds were evaluated, and the assay was designed to mimic the half-lives of the antibiotics in vivo, i.e., 11.5 h for azithromycin, 5 h for clarithromycin, and 1 h for amoxicillin. Monolayers of HEp-2 cells were grown in the inserts for 2 days, after which H. pylori (clinical strain 88-23), was added to the system. Internalization was allowed for 12 h, and extracellular H. pylori cells were eradicated with gentamicin. The inserts were moved to the glass chamber, containing medium with 12.5 mg of either amoxicillin or azithromycin per liter or 2.4 mg of clarithromycin per liter. This represents 12.5, 50, and 80 times the extracellular minimum bactericidal concentration value, respectively. Samples were taken at 0, 2, 4, 6, 8, and 24 h. The HEp-2 cells were lysed, and intracellular bacteria were counted by plating. Inserts with infected cells grown in drug-free medium were included as controls for each time interval. A 3-log10 reduction of H. pylori was achieved in the experiments with azithromycin, and a 4-log10 reduction was achieved in the clarithromycin experiments, while no intracellular effect was seen when amoxicillin was used. The antibiotic concentrations at the sampling intervals were 12.5, 3.1, 0.8, 0.2, 0.05, and 0 mg/liter for amoxicillin; 12.5, 11.5, 10, 9, 8, and 3 mg/liter for azithromycin; and 2.4, 1.8, 1.4, 1, 0.8, and 0 mg/liter for clarithromycin. This new model for pharmacokinetic studies provides a useful tool, with applications for a broad range of microorganisms.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9124830      PMCID: PMC163611     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  29 in total

1.  In-vitro activity of azithromycin in against intracellular Helicobacter pylori.

Authors:  K Hulten; O Cars; E Hjelm; L Engstrand
Journal:  J Antimicrob Chemother       Date:  1996-03       Impact factor: 5.790

2.  Antimicrobial activity and human pharmacology of amoxicillin.

Authors:  H C Neu
Journal:  J Infect Dis       Date:  1974-06       Impact factor: 5.226

3.  Comparative clinical pharmacology of three ampicillins and amoxicillin administered orally.

Authors:  H Lode; P Janisch; G Küpper; H Weuta
Journal:  J Infect Dis       Date:  1974-06       Impact factor: 5.226

4.  Protection of phagocytized bacteria from the killing action of antibiotics.

Authors:  B Holmes; P G Quie; D B Windhorst; B Pollara; R A Good
Journal:  Nature       Date:  1966-06-11       Impact factor: 49.962

5.  Electron microscopic study of association between Helicobacter pylori and gastric and duodenal mucosa.

Authors:  L A Noach; T M Rolf; G N Tytgat
Journal:  J Clin Pathol       Date:  1994-08       Impact factor: 3.411

6.  Comparative clinical pharmacology of amoxicillin and ampicillin administered orally.

Authors:  C Gordon; C Regamey; W M Kirby
Journal:  Antimicrob Agents Chemother       Date:  1972-06       Impact factor: 5.191

7.  Limited efficacy of omeprazole-based dual and triple therapy for Helicobacter pylori: a randomized trial employing "optimal" dosing.

Authors:  L Laine; C Stein; G Neil
Journal:  Am J Gastroenterol       Date:  1995-09       Impact factor: 10.864

8.  Intragastric acidity as a predictor of the success of Helicobacter pylori eradication: a study in peptic ulcer patients with omeprazole and amoxicillin.

Authors:  J Labenz; M Stolte; A L Blum; I Jorias; F Leverkus; M Sollböhmer; J Bertrams; G Börsch
Journal:  Gut       Date:  1995-07       Impact factor: 23.059

9.  Antibiotic penetration of and bactericidal activity within endothelial cells.

Authors:  R O Darouiche; R J Hamill
Journal:  Antimicrob Agents Chemother       Date:  1994-05       Impact factor: 5.191

10.  Bactericidal and morphological effects of amoxicillin on Helicobacter pylori.

Authors:  V Berry; K Jennings; G Woodnutt
Journal:  Antimicrob Agents Chemother       Date:  1995-08       Impact factor: 5.191

View more
  5 in total

Review 1.  Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: kill curves versus MIC.

Authors:  Markus Mueller; Amparo de la Peña; Hartmut Derendorf
Journal:  Antimicrob Agents Chemother       Date:  2004-02       Impact factor: 5.191

Review 2.  Interactions among strategies associated with bacterial infection: pathogenicity, epidemicity, and antibiotic resistance.

Authors:  José L Martínez; Fernando Baquero
Journal:  Clin Microbiol Rev       Date:  2002-10       Impact factor: 26.132

3.  In vitro pharmacodynamics of the new ketolides HMR 3004 and HMR 3647 (Telithromycin) against Chlamydia pneumoniae.

Authors:  I Gustafsson; E Hjelm; O Cars
Journal:  Antimicrob Agents Chemother       Date:  2000-07       Impact factor: 5.191

4.  A Diffusion-Based and Dynamic 3D-Printed Device That Enables Parallel in Vitro Pharmacokinetic Profiling of Molecules.

Authors:  Sarah Y Lockwood; Jayda E Meisel; Frederick J Monsma; Dana M Spence
Journal:  Anal Chem       Date:  2016-01-15       Impact factor: 6.986

5.  In vitro pharmacodynamic studies of activities of ketolides HMR 3647 (Telithromycin) and HMR 3004 against extracellular or intracellular Helicobacter pylori.

Authors:  I Gustafsson; L Engstrand; O Cars
Journal:  Antimicrob Agents Chemother       Date:  2001-01       Impact factor: 5.191

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.